- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05361018
Sensorimotor Training Using Whole Body Vibration Exercise to Reduce Chemotherapy-induced Peripheral Neuropathy (Sensi-Ex)
SensiEx - Sensorimotor Training Using Whole Body Vibration Exercise to Reduce Chemotherapy-induced Peripheral Neuropathy After Treatment for Breast Cancer a Randomized Controlled Pilot Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aim: To (a) compare the effects of WBV exercise compared to regular cardiovascular and resistance exercise (CAR) on the primary outcome of (a) CIPN symptoms and secondary outcomes of (b) balance, physical function, and quality of life.
Based on previous pilot study findings, we hypothesize that WBV exercise compared to CAR will reduce relevant symptoms to a larger degree, such as the loss of peripheral deep sensitivity, pain, weakened or absent reflexes and loss of balance control (aim a) and that patients will experience an improvement in physical function and quality of life (aim b).
The study employs a prospective, multicenter, two-armed, randomized controlled design. Study participants will be informed about the study procedure and sign a written informed consent. Patients will then be assigned randomly either to the WBV group or the CAR group. Patients allocated to the WBV group receive a defined WBV exercise program twice a week in addition to their usual treatment. Patients in conventional aerobic and resistance exercise (CAR) group will receive a defined exercise program twice a week in addition to their usual treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 11447
- Karolinska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- patients with breast cancer, aged 18-80 years,
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2,
- completed chemotherapy in the past 3 months. Experiencing symptoms of CIPN
Exclusion Criteria:
- pre-existing neuropathy of other cause (eg, diabetes),
- given contraindications for WBV including instable bone metastases and severe cardiovascular disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Whole Body Vibration exercise - WBV
The vibration exercises take place on a tri-planar vibration platform (Power Plate) according to the initially determined setting for each individual (highest, though feasible neuromuscular response). .
Each session lasts for about 15-30 min in total, leaving sufficient time for regeneration.
Training consists of at least four vibration exercises, chosen from a standardized pool of exercises with increasing difficulty in order to allow for individual, optimal progression.
All sessions and adherence are documented by the exercise supervisor.
Adverse events are documented, and patients asked to give feedback regarding the feasibility and subjective impression of each individual setting.
All training sessions will be supervised.
The participants rating of perceived exertion (RPE) will be assessed immediately after each set of exercise.
|
participants will be randomised to two different training interventions
Other Names:
|
|
Active Comparator: Conventional Aerobic and Resistance exercise - CAR
exercise sessions commence with 20 min of moderate intensity continuous aerobic exercise at a rating of perceived exertion (RPE) of 13-15 on the Borg scale.
Participants complete both resistance exercises and high intensity intermittent aerobic exercises during each session.
The resistance training regimen consists of 8 exercises (leg press, biceps curls, triceps extensions, bench press, shoulder press, standing row, sit ups/Russian weighted abdominal twist, and prone lying back extensions.
Participants complete 2 sets of 8-12 repetitions at an initial intensity of 70 % of their estimated 1 repetition maximum (1-RM) strength and increase to 80 % of estimated 1-RM when more than 12 repetitions can be correctly performed by the participant
|
participants will be randomised to two different training interventions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Chemotherapy-induced peripheral neuropathy subjective symptoms, less symptoms
Time Frame: Change from Baseline to 12 weeks
|
Chemotherapy-induced peripheral neuropathy assessed by The Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT) symptom experience scale
|
Change from Baseline to 12 weeks
|
|
Chemotherapy-induced peripheral neuropathy sensory loss assessment, increased sensation
Time Frame: Change from Baseline to 12 weeks
|
Monofilament testing will be performed to further quantify sensory loss at all three time points by a specially trained researcher with Von Frey Monofilament Kit using established procedures by Dyck and colleagues
|
Change from Baseline to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Balance control, improved balance
Time Frame: Change from Baseline to12 weeks
|
Unipedal Stance Time test
|
Change from Baseline to12 weeks
|
|
Performance status, improved balance and function
Time Frame: Change from Baseline to 12 weeks
|
Timed Up and Go (TUG)
|
Change from Baseline to 12 weeks
|
|
Additional balance assessment
Time Frame: Change from Baseline to 12 weeks
|
Modified Clinical Test for Sensory Interaction in Balance (mCTSIB)
|
Change from Baseline to 12 weeks
|
|
Pain related to CIPN, less pain than baseline
Time Frame: Change from Baseline to 12 weeks
|
The painDETECT questionnaire
|
Change from Baseline to 12 weeks
|
|
Quality of Life assessment, improved quality of life
Time Frame: Change from Baseline to 12 weeks
|
The EORTC-QLQ-C30 questionnaire
|
Change from Baseline to 12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yvonne Wengström, Professor, Karolinska Institutet
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Yvonne Wengstrom
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.